With respect of actional alterations of NSCLC, EGFR mutations account for approximately 18.9–51.4% of NSCLC, followed by KRAS mutations (11.2–32%), ALK rearrangements (3–7%), MET alterations (1–5%), HER2 alterations (3%), BRAF mutations (1.5–8%), ROS1 rearrangements (1–2%), RET mutations (1–2%), and NTRK mutations (less than 1%) [5–10]. Here, ALK is linked to non-small cell lung carcinoma.